Levetan Claresa MD Wynnewood, PA - 19096

Levetan Claresa MD is categorized under Kidney Dialysis Centers in Wynnewood, PA and active since 1973.

Levetan Claresa MD was established in 1973, and today employs 1 to 4, earning $500.000 to $999.999 per year. This is a Kidney Dialysis Centers business, which does work in the B2C market, and is classified as a Kidney Dialysis Centers, under code number 6211110 by the NAICS.

If you are seeking more information, feel free to contact Claresa Levetan at the company’s single location by writing to 100 East Lancaster Avenue # 361, Wynnewood, Pennsylvania PA 19096 or by phoning (610) 645-2000. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Levetan Claresa MD
Contact Person: Claresa Levetan
Address: 100 East Lancaster Avenue # 361, Wynnewood, Pennsylvania 19096
Phone Number: (610) 645-2000
Website Address: nephassociates.com
Annual Revenue (USD): $500.000 to $999.999
Founded: 1973
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2C (Business to Consumer)
Business Category: Kidney Dialysis Centers
SIC Code: 8092
NAICS Code: 6211110
Share This Business:

Levetan Claresa MD was started in 1973 to provide professional Kidney Dialysis Centers under the SIC code 8092 and NAICS code 6211110. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $500.000 to $999.999 per annum.

Feel free to contact Claresa Levetan for inquiries that concern Levetan Claresa MD by calling the company number (610) 645-2000, as your correspondence is most welcome. Additionally, the physical location of the single location of Levetan Claresa MD can be found at the coordinates 40.000948,-75.275269 as well as the street address 100 East Lancaster Avenue # 361 in Wynnewood, Pennsylvania 19096.

For its online presence, you may visit Levetan Claresa MD’s website at nephassociates.com and engage with its social media outlets through on Twitter and on Facebook.